Bal Pharma Ltd vs Glenmark Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Bal Pharma Ltd is ₹ 75.6 as of 30 Apr 15:30 . The P/E Ratio of Bal Pharma Ltd changed from 16.8 on March 2021 to 18.4 on March 2025 . This represents a CAGR of 1.84% over 5 yearsThe P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 13.5 on March 2021 to 41.5 on March 2025 . This represents a CAGR of 25.18% over 5 years The Market Cap of Bal Pharma Ltd changed from ₹ 79.67 crore on March 2021 to ₹ 132.4 crore on March 2025 . This represents a CAGR of 10.69% over 5 yearsThe Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 13108 crore on March 2021 to ₹ 43458 crore on March 2025 . This represents a CAGR of 27.09% over 5 years The revenue of Bal Pharma Ltd for the Dec '25 is ₹ 88.02 crore as compare to the Sep '25 revenue of ₹ 75.14 crore. This represent the growth of 17.14% The revenue of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 3945 crore as compare to the Sep '25 revenue of ₹ 6247 crore. This represent the decline of -36.85% The ebitda of Bal Pharma Ltd for the Dec '25 is ₹ 9.87 crore as compare to the Sep '25 ebitda of ₹ 6.85 crore. This represent the growth of 44.09% The ebitda of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 729.88 crore as compare to the Sep '25 ebitda of ₹ 1175 crore. This represent the decline of -37.89% The net profit of Bal Pharma Ltd changed from ₹ 0.26 crore to ₹ 1.79 crore over 7 quarters. This represents a CAGR of 201.15% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 340.24 crore to ₹ 403.23 crore over 7 quarters. This represents a CAGR of 10.19% The Dividend Payout of Bal Pharma Ltd changed from 16.29 % on March 2021 to 24.49 % on March 2025 . This represents a CAGR of 8.50% over 5 yearsThe Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 4.28 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of 0.46% over 5 years .

About Bal Pharma Ltd

Bal Pharma Limited (BPL), a member of the Mcro Laboratories Group, was incorporated as a private limited company in May 1987.
In March 1990, BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which, BPL commenced manufacturing formulations. BPL manufactures and markets pharmaceutical formulations -- paracetamol, aluminium hydroxide, povidone iodine, alprazolam, gliclazide, griseofulvin, lactobacillus, rifampicin, piroxicam amoxycillin, etc.
The company promotes its products through the common sales force of the group but proposes to induct its own soon.
It came out with a public issue in Feb.'95 for manufacture of bulk drugs and expansion of pharmaceutical formulations.

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
Its branded generics business has a significant presence in markets across emerging economies including India.

FAQs for the comparison of Bal Pharma Ltd and Glenmark Pharmaceuticals Ltd

Which company has a larger market capitalization, Bal Pharma Ltd or Glenmark Pharmaceuticals Ltd?

Market cap of Bal Pharma Ltd is 120 Cr while Market cap of Glenmark Pharmaceuticals Ltd is 67,884 Cr

What are the key factors driving the stock performance of Bal Pharma Ltd and Glenmark Pharmaceuticals Ltd?

The stock performance of Bal Pharma Ltd and Glenmark Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bal Pharma Ltd and Glenmark Pharmaceuticals Ltd?

As of May 3, 2026, the Bal Pharma Ltd stock price is INR ₹75.6. On the other hand, Glenmark Pharmaceuticals Ltd stock price is INR ₹2405.55.

How do dividend payouts of Bal Pharma Ltd and Glenmark Pharmaceuticals Ltd compare?

To compare the dividend payouts of Bal Pharma Ltd and Glenmark Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.